Amgen Inc. vs Vericel Corporation: SG&A Expense Trends

SG&A Expense Trends: Amgen Inc. vs Vericel Corporation

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. Over the past decade, Amgen Inc. and Vericel Corporation have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amgen's SG&A expenses have seen a steady increase, peaking at approximately $6.2 billion in 2023, marking a 31% rise from 2014. In contrast, Vericel Corporation, a smaller entity, has shown a more dramatic growth trajectory, with SG&A expenses surging by over 770% during the same period, reaching around $121 million in 2023. This stark difference highlights the diverse financial strategies and growth phases of these companies. While Amgen's expenses reflect its established market presence, Vericel's rapid increase underscores its aggressive expansion efforts. These insights offer a window into the strategic priorities shaping the future of these pharmaceutical giants.